See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $299B | 4.6x | 10.0x | |
| $191B | 3.1x | 7.7x | |
| $125B | 2.4x | 7.9x | |
| $122B | 2.8x | 8.2x | |
| $66.6B | 4.1x | 12.2x | |
| $57.4B | 6.7x | 21.6x | |
| $12.1B | 6.3x | -3.8x | |
| $10.0B | 3.2x | -8.1x | |
| $8.3B | 4.0x | -43.4x | |
| $7.9B | 8.1x | 26.2x | |
| $7.8B | 26.5x | 625.5x | |
| $4.7B | n/a | -5.5x | |
| $4.3B | 10.0x | 30.5x | |
| $3.5B | 5.2x | 14.1x | |
| $3.4B | n/a | n/a | |
| $3.3B | 29.4x | n/a | |
| $2.7B | 7.5x | 25.9x | |
| $2.6B | 6.2x | 23.3x | |
| $2.5B | n/a | n/a | |
| $2.3B | n/a | n/a | |
| $2.3B | 5.1x | -80.4x | |
| $2.3B | 289.5x | -10.7x | |
| $2.0B | 2.2x | 6.0x | |
| $2.0B | 8.0x | -5.4x | |
| $1.6B | 6.6x | 281.5x | |
| $1.5B | n/a | n/a | |
| $1.4B | 4.2x | 57.5x | |
| $1.4B | n/a | n/a | |
| $1.3B | n/a | n/a | |
| $1.3B | 487.0x | -8.5x | |
| $1.3B | 6.9x | 18.8x | |
| $1.2B | n/a | n/a | |
| $1.2B | n/a | n/a | |
| $1.1B | 37.3x | -31.0x | |
| $1.1B | 432.8x | -4.3x | |
| $1.1B | 12.8x | -32.3x | |
| $1.0B | 5.1x | -38.8x | |
| $959M | 4.8x | -18.7x | |
| $905M | 5.7x | 12.2x | |
| $877M | n/a | n/a | |
| $847M | 18.1x | -4.3x | |
| $822M | n/a | -10.6x | |
| $787M | 4.2x | n/a | |
| $752M | 0.7x | 2.0x | |
| $606M | 12.0x | -10.9x | |
| $582M | 7.0x | -53.6x | |
| $556M | n/a | n/a | |
| $546M | n/a | n/a | |
| $541M | 12.6x | -3.6x | |
| $534M | n/a | n/a | |
| $509M | n/a | n/a | |
| $506M | 90.4x | n/a | |
| $495M | n/a | n/a | |
| $469M | n/a | n/a | |
| $456M | 22.0x | -0.9x | |
| $451M | n/a | n/a | |
| $418M | 2.3x | 9.5x | |
| $402M | n/a | n/a | |
| $368M | n/a | n/a | |
| $354M | n/a | -2.1x | |
| $327M | n/a | n/a | |
| $325M | 258.6x | -1.0x | |
| $297M | n/a | n/a | |
| $284M | n/a | -10.3x | |
| $246M | n/a | -5.4x | |
| $235M | 7.1x | n/a | |
| $235M | n/a | -9.1x | |
| $212M | 9412.7x | -1.2x | |
| $204M | n/a | n/a | |
| $199M | 166.1x | -4.2x | |
| $187M | 102715.5x | -0.9x | |
| $167M | 1.3x | n/a | |
| $164M | 15.1x | -4.2x | |
| $163M | 57.5x | -8.6x | |
| $135M | n/a | n/a | |
| $130M | n/a | n/a | |
| $129M | n/a | n/a | |
| $127M | n/a | n/a | |
| $123M | n/a | n/a | |
| $123M | 2.5x | -42.0x | |
| $117M | 16.2x | n/a | |
| $104M | n/a | n/a | |
| $96.4M | n/a | -3.9x | |
| $96.2M | n/a | n/a | |
| $95.5M | n/a | n/a | |
| $85.7M | n/a | n/a | |
| $81.7M | 1.1x | -0.3x | |
| $80.1M | n/a | n/a | |
| $67.8M | 767.2x | n/a | |
| $66.1M | n/a | -0.4x | |
| $62.6M | n/a | n/a | |
| $62.6M | 19.8x | -1.7x | |
| $60.6M | 30.8x | n/a | |
| $56.2M | 9.5x | n/a | |
| $54.4M | n/a | n/a | |
| $54.1M | n/a | n/a | |
| $49.7M | 1.1x | -0.3x | |
| $47.0M | n/a | n/a | |
| $45.3M | n/a | n/a | |
| $43.8M | n/a | n/a | |
| $43.5M | n/a | -1.3x | |
| $40.9M | n/a | n/a | |
| $36.6M | 0.3x | 1.0x | |
| $35.0M | n/a | n/a | |
| $34.5M | 6.9x | n/a | |
| $24.6M | n/a | -0.3x | |
| $21.8M | n/a | n/a | |
| $20.4M | n/a | n/a | |
| $18.8M | 18.8x | -0.7x | |
| $18.2M | n/a | n/a | |
| $16.7M | 250.2x | n/a | |
| $15.1M | n/a | n/a | |
| $13.7M | 1.3x | n/a | |
| $12.8M | 1.8x | n/a | |
| $12.8M | 4.1x | -0.9x | |
| $12.0M | 8.6x | -0.7x | |
| $9.4M | 350.0x | n/a | |
| $5.1M | 0.9x | n/a | |
| $3.8M | 0.0x | n/a | |
| $3.5M | 1.4x | n/a | |
| -$1.7M | n/a | 0.0x | |
| -$1.8M | n/a | n/a | |
| -$11.3M | -4.0x | n/a | |
| -$15.1M | -2.3x | 0.1x | |
| -$24.1M | -2.3x | 0.2x | |
| -$32.9M | n/a | n/a | |
| -$53.3M | n/a | n/a | |
| -$66.5M | n/a | n/a | |
| -$85.3M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies